Protinhi Therapeutics semi-finalist iin ZELSIF
Protinhi Therapeutics, a company located at Noviotech Campus Nijmegen, is nominated as a semi-finalist in ZELSIF this year, and will be presenting their journey to European and Chinese medical experts and investors during the event on the 16th of December.
The ZELSIF 2022 International Top 15 winners will receive the “ZELSIF 2022” award, which goes along with the privileged opportunity to introduce their solutions to Chinese healthcare experts, investors, and industrials through an online pitch presentation. In the next two weeks, the semi-finalist companies will compete for the top 7 final winners who will receive further awards in cash.
Protinhi Therapeutics is an early-stage biotech company aiming to combat (emerging) viral infectious diseases with a high unmet medical need via protease inhibition. With their proprietary technology platform, they are actively developing novel antiviral drugs that inhibit proteases and block viral replication. The aim for easy-to-administer drugs able to treat in epidemic and pandemic situations.
Posted by Karina Garcia, Kadans Science Partner.
Op 12 oktober vond voor de derde keer de Radboudumc Investment Day plaats. Wetenschappers, ondernemers en investeerders uit de life sciences & health sector kwamen...
On October 1 the Autumn Call from imec.istart.nl opens up, allowing you to apply to the worlds number 1 business accelerator program. The 12-month Imec.istart.nl...